Author: Apotex Inc.

Posted Date:

April 10, 2026

Apotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic® (Semaglutide Injection) in Partnership with Orbicular

Apotex Inc.

April 10, 2026
Apotex Strengthens Osteoporosis Care in Canada with Health Canada’s Approval of DENOZA™, a Denosumab Biosimilar

Apotex Inc.

April 7, 2026
Apotex announces leadership changes

Apotex Inc.

March 30, 2026
Apotex Expands Canadian Ophthalmology Portfolio with Health Canada’s Approval of CLOBIVIS™ (Clobetasol Propionate Ophthalmic Suspension, 0.05%)

Apotex Inc.

March 25, 2026
Apotex licenses exclusive Canadian rights to testosterone replacement therapy Nebido® from Grünenthal

Apotex Inc.

February 13, 2026
Apotex licenses exclusive Canadian rights to testosterone replacement therapy Nebido® from Grünenthal

Apotex Inc.

February 11, 2026